Consistently, the tumour tissues from stage III and IV metastatic melanoma patients had significantly increased ILF2 protein average levels (1.56 and 1.62 fold‐change, respectively) compared to the primary melanoma tissues (Figure 1E). This evidence concerns the gene ILF2 and melanoma.